Adult urologyCombination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study
Section snippets
Patient population
During a 2-year period, 40 patients were recruited for this randomized Phase II study. Patients were eligible if they had Eastern Cooperative Oncology Group performance status of 0 to 3, had adenocarcinoma of the prostate that was progressing despite androgen deprivation, with measurable or assessable metastases, and had not received prior chemotherapy, diethylstilbestrol, estramustine, dexamethasone, or a somatostatin analog. All antiandrogen therapy was discontinued for at least 1 month, and
Results
The patient and disease characteristics are shown in Table I and were well balanced between the two treatment groups.
The PSA response data are shown in Table II. Approximately one half of the patients in each group achieved at least a 50% reduction in their PSA level. The median time for a PSA response was 7 weeks in the chemotherapy group and 9 weeks in the combination therapy group. An improved or stable bone scan was noted in 59% and 44%, respectively, of patients with osseous disease in
Comment
In our patients with HRPC, chemotherapy with estramustine and etoposide was compared with the combination of the somatostatin analog lanreotide and dexamethasone in addition to androgen ablation by orchiectomy or the LHRH analog triptorelin. The two treatments resulted in similar responses in terms of PSA level, measurable disease, osseous disease, time to progression, and overall survival. The quality of life, expressed as the performance status and pain score, did not differ between the two
Acknowledgements
To the following physicians for contributing patients to the study: Charalambos Arvanitis, Athanasios Bekos, Michael Bourounis, Antonios Farmakis, Charalambos Fasoulakis, Paraskevas Kalomiris, Ioannis Kastriotis, Petros Kirtsis, Theoharis Lambou, Michael Likourinas, Konstantinos Papoulis, Iraklis Poulias, Zoucher Sami, and Athanasios Tsintavis.
References (29)
- et al.
Treatment of patients with advanced cancer of the prostatephase III trial, Zoladex against castration—a study of the British prostate group
J Steroid Biochem
(1987) - et al.
Oral estramustine and oral etoposide for hormone-refractory prostate cancer
Urology
(1997) - et al.
Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin-apoptosis
Urology
(1998) - et al.
Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate
Cancer Res
(1994) - et al.
Prostatic carcinoma
J Med
(1968) - et al.
Advance prostatic carcinomaearly vs. late endocrine therapy
Urol Clin North Am
(1991) Hormonal therapy in the treatment of carcinoma of the prostate
Cancer
(1995)Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
J Clin Oncol
(1985)- et al.
Phase II study of estramustine phosphate in advanced hormone-refractory prostate cancer with increasing prostate specific antigen
J Urol
(1991) - et al.
Phase II study of estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
J Clin Oncol
(1994)
The assessment of disease aggressivity in stage D2 prostate cancer patients
Anticancer Res
Mechanisms of lytic and blastic disease of bone
Clin Orthopaed Rel Res
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
Clin Endocrinol (Oxf)
Urokinase-type plasminogen activatora paracrine factor regulating the bioavailability of IGFs in PA-III cel-induced osteoblastic metastases
Anticancer Res
Cited by (44)
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer
2018, Clinical Genitourinary CancerCitation Excerpt :Laboratory investigations have established a strong rationale for using sst receptor analogues in prostate cancer and have postulated multiple mechanisms for the synergy including IGF-1 blockade, modulating the sst receptors 2 and 5, overcoming P-glycoprotein mediated docetaxel resistance, and inducing proapoptotic proteins and inhibiting antiapoptotic proteins. A clinical trial was conducted randomizing patients with mCRPC to receive estramustine chemotherapy or a combination of lanreotide and steroids.18 The outcomes of pain control, PSA, and clinical response, and OS (18 months median OS) were no different between the 2 arms.
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies
2014, Critical Reviews in Oncology/HematologyNeuroendocrine differentiation of prostate cancer: A literature review
2014, Urologia ColombianaPhase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
2009, Annals of OncologyCitation Excerpt :Although grade 3/4 toxicity at 22.6% was higher than expected, overall the treatment was manageable and less than encountered with docetaxel. [1] Three patients developed deep vein thrombosis, less than the four (6%) cases reported by Pienta et al. [20] and two (10%) cases reported by Dimopoulos et al. [22]. However, a meta-analysis of 23 studies involving 896 patients treated with estramustine concluded that the risk of thromboembolic events was low (0.07) and not dose related [27].
Clinical efficacy of a novel therapeutic principle, anakoinosis
2018, Frontiers in Pharmacology